Transcriptional regulation of HSCs in Aging and MDS reveals DDIT3 as a Potential Driver of Transformation

Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell (HSC) malignancies characterized by ineffective hematopoiesis with increased incidence in elderly individuals. Genetic alterations do not fully explain the molecular pathogenesis of the disease, indicating that other types of lesions may play a role in its development. In this work, we analyzed the transcriptional lesions of human HSCs, demonstrating how aging and MDS are characterized by a complex transcriptional rewiring that manifests as diverse linear and non-linear transcriptional dynamisms. While aging-associated lesions seemed to predispose elderly HSCs to myeloid transformation, disease-specific alterations may be involved in triggering MDS development. Among MDS-specific lesions, we detected the overexpression of the transcription factor DDIT3. Exogenous upregulation of DDIT3 in human healthy HSCs induced an MDS-like transcriptional state, and a delay in erythropoiesis, with an accumulation of cells in early stages of erythroid differentiation, as determined by single-cell RNA-sequencing. Increased DDIT3 expression was associated with downregulation of transcription factors required for normal erythropoiesis, such as KLF1, TAL1 or SOX6, and with a failure in the activation of their erythroid transcriptional programs. Finally, DDIT3 knockdown in CD34+ cells from MDS patients was able to restore erythropoiesis, as demonstrated by immunophenotypic and transcriptional profiling. These results demonstrate that DDIT3 may be a driver of MDS transformation, and a potential therapeutic target to restore the inefficient erythropoiesis characterizing these patients. KEY POINTS Human HSCs undergo a complex transcriptional rewiring in aging and MDS that may contribute to myeloid transformation. DDIT3 overexpression induces a failure in the activation of erythroid transcriptional programs, leading to inefficient erythropoiesis.

[1]  Heather J. Lee,et al.  Unravelling the Epigenome of Myelodysplastic Syndrome: Diagnosis, Prognosis, and Response to Therapy , 2020, Cancers.

[2]  R. Schneider,et al.  Inflammatory bone marrow microenvironment. , 2019, Hematology. American Society of Hematology. Education Program.

[3]  E. Papaemmanuil,et al.  Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression , 2019, Genome Medicine.

[4]  K. Do,et al.  Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes , 2019, Leukemia.

[5]  Linden J Gearing,et al.  CiiiDER: A tool for predicting and analysing transcription factor binding sites , 2019, PloS one.

[6]  S. Ogawa.  Genetics of MDS. , 2019, Blood.

[7]  M. Alcalay,et al.  Adhesion Deregulation in Acute Myeloid Leukaemia , 2019, Cells.

[8]  A. Gavin,et al.  Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. , 2018, Blood.

[9]  Rui Chen,et al.  Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells , 2018, Leukemia & lymphoma.

[10]  N. Taylor,et al.  Developmental differences between neonatal and adult human erythropoiesis , 2018, American journal of hematology.

[11]  D. Banerjee,et al.  Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS. , 2017, Blood cells, molecules & diseases.

[12]  Benjamin D. Greenbaum,et al.  Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses , 2017, Cell.

[13]  S. Miyano,et al.  Dynamics of clonal evolution in myelodysplastic syndromes , 2016, Nature Genetics.

[14]  B. Ebert,et al.  The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia , 2016, Nature Reviews Cancer.

[15]  S. Soneji,et al.  Human and Murine Hematopoietic Stem Cell Aging Is Associated with Functional Impairments and Intrinsic Megakaryocytic/Erythroid Bias , 2016, PloS one.

[16]  K. Ghosh,et al.  Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia. , 2016, Asian Pacific journal of cancer prevention : APJCP.

[17]  P. Nederkoorn,et al.  Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations , 2015, Pediatric Rheumatology.

[18]  J. Boultwood,et al.  The molecular pathogenesis of the myelodysplastic syndromes , 2015, European journal of haematology.

[19]  Carsten Peterson,et al.  Single-Cell Network Analysis Identifies DDIT3 as a Nodal Lineage Regulator in Hematopoiesis , 2015, Cell reports.

[20]  A. Verma,et al.  Stem cell origin of myelodysplastic syndromes , 2014, Oncogene.

[21]  Randy J. Read,et al.  Transcriptional diversity during lineage commitment of human blood progenitors , 2014, Science.

[22]  J. Nikolich-Žugich,et al.  Aging of the T Cell Compartment in Mice and Humans: From No Naive Expectations to Foggy Memories , 2014, The Journal of Immunology.

[23]  Wei Li,et al.  Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells. , 2014, Cell stem cell.

[24]  S. Linnarsson,et al.  Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. , 2014, Cancer cell.

[25]  Vivek Jayaswal,et al.  Gene profiling reveals association between altered Wnt signaling and loss of T-cell potential with age in human hematopoietic stem cells , 2014, Aging cell.

[26]  J. Li,et al.  Global transcriptome analyses of human and murine terminal erythroid differentiation. , 2014, Blood.

[27]  B. Göttgens,et al.  Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal. , 2014, Cell stem cell.

[28]  I. Amit,et al.  Massively Parallel Single-Cell RNA-Seq for Marker-Free Decomposition of Tissues into Cell Types , 2014, Science.

[29]  J. Gribben,et al.  HIF-2α protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress. , 2013, Cell stem cell.

[30]  Ruth R. Montgomery,et al.  Age-dependent dysregulation of innate immunity , 2013, Nature Reviews Immunology.

[31]  A. Raza,et al.  The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes , 2012, Nature Reviews Cancer.

[32]  M. Cancro,et al.  B cell maintenance and function in aging. , 2012, Seminars in immunology.

[33]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[34]  Debashis Sahoo,et al.  Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age , 2011, Proceedings of the National Academy of Sciences.

[35]  Mamoru Ito,et al.  Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells. , 2011, Blood.

[36]  O. Abdel-Wahab,et al.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. , 2011, Cancer cell.

[37]  Berthold Göttgens,et al.  Transcriptional regulation of haematopoietic transcription factors , 2011, Stem Cell Research & Therapy.

[38]  J. Qian,et al.  Aberrant methylation of DNA-damage-inducible transcript 3 promoter is a common event in patients with myelodysplastic syndrome. , 2010, Leukemia research.

[39]  M Cazzola,et al.  Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells , 2010, Leukemia.

[40]  J. Stebbing,et al.  Epigenetic modifications in AML and MDS. , 2010, Leukemia research.

[41]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[42]  I. Weissman,et al.  Stems Cells and the Pathways to Aging and Cancer , 2008, Cell.

[43]  M. Cazzola,et al.  Gene expression profiling of CD34+ cells in patients with the 5q− syndrome , 2007, British journal of haematology.

[44]  S. Mayne,et al.  Myelodysplastic syndromes , 2007, Cancer.

[45]  Li Wang,et al.  Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. , 2006, Blood.

[46]  J. Qian,et al.  Gene expression profiling of the bone marrow mononuclear cells from patients with myelodysplastic syndrome. , 2005, Oncology reports.

[47]  I. Weissman,et al.  Cell intrinsic alterations underlie hematopoietic stem cell aging. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[48]  J. Rowe,et al.  The relationship of patient age to the pathobiology of the clonal myeloid diseases. , 2004, Seminars in oncology.

[49]  R. Pereira,et al.  CCAAT/enhancer binding protein homologous protein (DDIT3) induces osteoblastic cell differentiation. , 2004, Endocrinology.

[50]  Y. Yamashita,et al.  DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome , 2003, British journal of haematology.

[51]  M. Lane,et al.  Role of C/EBP homologous protein (CHOP-10) in the programmed activation of CCAAT/enhancer-binding protein-beta during adipogenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[52]  T. Flores,et al.  The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice , 2000, Oncogene.

[53]  X. Wang,et al.  Inhibition of adipogenesis by the stress‐induced protein CHOP (Gadd153). , 1995, The EMBO journal.

[54]  José Nueda,et al.  Revised Papers , 2022 .

[55]  J. Qian,et al.  Decreased expression of CCAAT/enhancer binding protein zeta (C/EBPzeta) in patients with different myeloid diseases. , 2005, Leukemia research.